pyrimethamine has been researched along with Infant, Small for Gestational Age in 3 studies
Maloprim: contains above 2 cpds
Infant, Small for Gestational Age: An infant having a birth weight lower than expected for its gestational age.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Ategeka, J | 1 |
Kakuru, A | 1 |
Kajubi, R | 1 |
Wasswa, R | 1 |
Ochokoru, H | 1 |
Arinaitwe, E | 1 |
Yeka, A | 1 |
Jagannathan, P | 1 |
Kamya, MR | 1 |
Muehlenbachs, A | 1 |
Chico, RM | 1 |
Dorsey, G | 1 |
Di Carlo, P | 1 |
Mazzola, A | 1 |
Romano, A | 1 |
Schimmenti, MG | 1 |
Colicchia, P | 1 |
Bellipanni, P | 1 |
Titone, L | 1 |
Mitchell, CD | 1 |
Erlich, SS | 1 |
Mastrucci, MT | 1 |
Hutto, SC | 1 |
Parks, WP | 1 |
Scott, GB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622] | Phase 3 | 782 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 44 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 24 |
Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 19 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination
Intervention | episodes per person year (Number) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 1.98 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1.71 |
Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 9 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 |
Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery
Intervention | weeks (Mean) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 39.4 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 39.6 |
Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 60 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 54 |
All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 54 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 43 |
"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | routine hemoglobin measurement (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 222 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 216 |
hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
Intervention | blood smears (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 344 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 357 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
Intervention | blood smears (Count of Units) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 519 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 9 |
Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1 |
Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) |
---|---|
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 197 |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 94 |
Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery
Intervention | Participants (Count of Participants) | |
---|---|---|
LAMP | Microscopy | |
Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 | 1 |
Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 71 | 29 |
3 other studies available for pyrimethamine and Infant, Small for Gestational Age
Article | Year |
---|---|
Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infan | 2020 |
[Postnatal follow-up of infants born to mothers with certain Toxoplasma gondii infection: evaluation of prenatal management].
Topics: Adolescent; Adult; Amniocentesis; Animals; Antibodies, Protozoan; Antiprotozoal Agents; Chorioretini | 2005 |
Congenital toxoplasmosis occurring in infants perinatally infected with human immunodeficiency virus 1.
Topics: Acquired Immunodeficiency Syndrome; Animals; Central Nervous System Diseases; Family Health; Female; | 1990 |